FLASCO

NCCN has published updates to theNCCN Guidelines® and NCCN Compendium® for Penile Cancer.

  • FLASCO
  • January 12, 2017

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Penile Cancer. These NCCN Guidelines® are currently available as Version 1.2017.

  • Primary treatment
    • Tis or Ta disease (PN-1)
      • The second option was revised: “Wide local excision .”
      • The fifth option was added: “Mohs surgery in select cases (category 2B).”
    • T1, grade 1-2 (PN-2)
      • The second option was added: “Glansectomy in select cases.”
      • The third option was added: “Mohs surgery in select cases (category 2B).”
    • T1, grade 3-4 (PN-2)
      • The option of “glansectomy” was removed.
    • Management of palpable non-bulky inguinal lymph node (PN-4)
      • For unilateral lymph node(s) <4 cm (mobile) and high-risk primary lesions, treated with ILND, the options for pN2-3 disease were revised by adding: “Pelvic lymph node dissection (PLND) ± adjuvant chemotherapy or chemoradiotherapy (category 2B).”
    • Local recurrence in inguinal region (PN-8)
      • The treatment algorithm was revised extensively.
    • Principles of Penile Organ-Sparing Approaches (PN-A)
      • For the topical therapies, imiquimod 5% and 5-FU cream 5%, dosing was added.
      • For laser therapy, new information was added along with a table of the therapeutic lasers commonly used to treat penile cancer including suggested settings.
    • Principles of Surgery (PN-B)
      • This section was revised extensively.
    • Principles of Radiotherapy (PN-C)
      • For primary radiation/chemoradiation therapy of T1-2, N0 disease, tumor <4 cm, the qualifier “preferred approach” was removed from “brachytherapy alone” and clarified as a category 2B recommendation.
      • EBRT was clarified as a category 2B recommendation and EBRT with concurrent chemotherapy was clarified as a category 3 recommendation.
    • Principles of Chemotherapy (PN-D)
      • For neoadjuvant chemotherapy prior to ILND or PLND, the first bullet was revised from “neoadjuvant, cisplatin-based chemotherapy…” to “neoadjuvant chemotherapy with TIP (paclitaxel, ifosfamide, and cisplatin)…”
      • For adjuvant chemotherapy following ILND or PLND, the first bullet was revised by adding: “5-FU plus cisplatin can be considered as an alternative to TIP in the adjuvant setting.”
      • For the regimen, 5-FU + cisplatin, the dosing was updated and a qualifier was added: “not recommended for neoadjuvant setting.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

Who’s Online

There are no users currently online